A composition for detecting Trichomonas vaginalis in humans and its application

By combining the RPA/CRISPR/Cas12a system with the ITS1-5.8S-ITS2 region target, specific primers and crRNA were designed to achieve rapid and accurate detection of Trichomonas vaginalis in canine and human fecal samples. This solves the problems of insufficient sensitivity and equipment dependence in existing technologies, and achieves rapid and efficient detection results.

CN123108175APending Publication Date: 2026-11-17JILIN UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611612858.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-19
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies are insufficient for the rapid and accurate detection of Trichomonas vaginalis in different scenarios, especially in the prevention and control of transmission between dogs and humans. Furthermore, existing methods are either not sensitive enough or rely on sophisticated instruments and professional personnel.

Method used

Using the RPA/CRISPR/Cas12a system combined with the ITS1-5.8S-ITS2 region as a target, specific RPA primers and crRNA were designed, and two interpretation methods, fluorescence and test strip, were provided to achieve rapid detection.

Benefits of technology

It enables rapid and accurate detection of Trichomonas vaginalis in canine and human fecal samples, reducing reliance on sophisticated equipment, shortening detection time, and providing visualized results with a sensitivity of 1.12 copies/μL.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123108175A_ABST
    Figure CN123108175A_ABST
Patent Text Reader

Abstract

This invention relates to the field of biodetection technology and provides a composition for detecting *Trichomonas vaginalis* in humans and its application. The composition includes crRNA and forward and reverse primers for RPA amplification. The sequence of the forward primer for RPA amplification is shown in SEQ ID NO. 6, and the sequence of the reverse primer for RPA amplification is shown in SEQ ID NO. 7. The sequence of the crRNA is shown in SEQ ID NO. 9. This invention has practical significance for the detection of *Trichomonas vaginalis* in fecal samples from various animals, including dogs and humans. It not only reduces the dependence on sophisticated detection equipment but also shortens the detection time and provides accurate detection results. After the reaction, the results can be observed visually under ultraviolet or blue light, or interpreted using lateral flow chromatography test strips. It achieves rapid and efficient detection and visualized results while possessing good specificity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biological detection technology, and in particular relates to a composition for detecting Trichomonas vaginalis in humans and its application. Background Technology

[0002] Trichomonas vaginalis is a globally distributed intestinal parasite that can infect various mammals, including humans, dogs, and cats. Recent studies have shown a close association between this parasite and diarrhea, as well as its ability to induce chronic intestinal inflammation and increase the risk of gastrointestinal cancers. In dogs, companion animals with close contact with humans, the infection rate of Trichomonas vaginalis can reach 27%-31% in some areas, and as high as 50% in dogs with diarrhea. Furthermore, the CC1 genotype prevalent in Chinese dogs is also the main genotype for human infection. Therefore, establishing a rapid detection method applicable to both dogs and humans is of great significance for controlling the spread of this parasite between the two populations.

[0003] Current detection methods for this parasite have limitations: microscopic examination has low sensitivity and difficulty in differentiating species; enzyme-linked immunosorbent assay (ELISA) and colloidal gold test strips are prone to missing low-concentration infected samples; nested polymerase chain reaction (nested PCR) and real-time quantitative polymerase chain reaction (qPCR), while having good sensitivity and specificity, rely on sophisticated instruments and professional personnel, making them unsuitable for on-site detection; recombinase polymerase amplification (RPA) technology does not require temperature-controlled equipment, but its sensitivity is insufficient and prone to false positives when used alone. Combining RPA with the clustered regularly spaced short palindromic repeats / Cas12a protein system (CRISPR / Cas12a system) can utilize the trans-cleavage activity activated by Cas12a after specific target recognition under crRNA guidance, further improving the sensitivity and specificity of detection.

[0004] Existing technologies disclose RPA / LAMP-CRISPR detection methods for Trichomonas vaginalis in humans, but all of them rely on... SPO11-1 Using genes as targets and relying solely on test strips for interpretation cannot meet the testing needs of different scenarios. SPO11-1 As protein-coding genes, their conservation is limited across species, while the internal transcribed spacer region of ribosomal DNA (rDNA) is highly conserved within species and exhibits greater variation across species, making it more suitable for species identification. In addition, rDNA exists in multiple copies in the genome, resulting in higher target abundance, which is beneficial for improving detection sensitivity. Summary of the Invention

[0005] The purpose of this invention is to provide a composition for detecting Trichomonas vaginalis in humans and its application, aiming to solve the problems mentioned in the background art.

[0006] To achieve the above objectives, the present invention provides the following technical solution: On the one hand, the present invention provides a composition for detecting Trichomonas vaginalis in humans, the composition comprising crRNA and forward and reverse primers for RPA amplification; The sequence of the forward primer used for RPA amplification is shown in SEQ ID NO.6, and the sequence of the reverse primer used for RPA amplification is shown in SEQ ID NO.7. The sequence of crRNA is shown in SEQ ID NO.9.

[0007] On the other hand, the present invention provides a kit for detecting Trichomonas vaginalis in humans, the kit comprising the above-mentioned composition for detecting Trichomonas vaginalis in humans.

[0008] Compared with the prior art, the specific beneficial effects of the present invention are as follows: This invention selects ITS1-5.8S-ITS2 Using the region as a target, specific RPA primer pairs and crRNA were designed, and two interpretation methods, fluorescence and test strip, were provided, which can detect canine and human samples simultaneously; This invention has practical significance for the detection of Trichomonas vaginalis in fecal samples from various animals, including dogs and humans. It not only reduces reliance on sophisticated detection equipment and shortens the detection time, but also provides accurate results. Clinical sample test results show that after isothermal amplification at 37°C and CRISPR / Cas12a reaction, the results can be observed visually under UV or blue light after the reaction, or interpreted using lateral flow chromatography test strips. The detection limit for the target DNA is 1.12 copies / μL by fluorescence method and 11.2 copies / μL by test strip method. This detection method not only has good specificity, but also achieves rapid and efficient detection and visualized results. Attached Figure Description

[0009] Figure 1 Agarose gel electrophoresis image of RPA primer screening provided in the embodiments of the present invention; M: 1000bp Marker, 1: F1 / R1, 2: F1 / R1 negative control, 3: F2 / R2, 4: F2 / R2 negative control, 5: F3 / R3, 6: F3 / R3 negative control; Figure 2 Agarose gel electrophoresis image of the in vitro transcription product of crRNA provided in an embodiment of the present invention; M: 500bp Marker, 1: crRNA1, 2: crRNA2; Figure 3 Real-time fluorescence signal curves of different crRNAs provided in the embodiments of the present invention; 1: crRNA1, 2: crRNA2, 3: crRNA1 negative control, 4: crRNA2 negative control; Figure 4Agarose gel electrophoresis quantitative images of the RPA reaction time optimization experiment provided in the embodiments of the present invention; 1: reaction 5 min, 2: reaction 10 min, 3: reaction 15 min, 4: reaction 20 min, 5: reaction 25 min, 6: reaction 30 min, 7: negative control; Figure 5 Fluorescence values ​​for the CRISPR / Cas12a cleavage time optimization experiment provided in this embodiment of the invention; 1: reaction 5 min, 2: reaction 10 min, 3: reaction 20 min, 4: reaction 30 min, 5: reaction 40 min, 6: reaction 50 min, 7: reaction 60 min; *: p <0.05; **: p <0.01, ns: no statistically significant difference; Figure 6 Fluorescence values ​​from the CRISPR / Cas12a reaction temperature optimization experiment provided in this embodiment of the invention; 1: 33℃, 2: 35℃, 3: 37℃, 4: 39℃, 5: 41℃; *: p <0.05; **: p <0.01, ns: no statistically significant difference; Figure 7 The specificity verification results provided by the embodiments of the present invention; A is the blue light view, B is the ultraviolet light view, C is the lateral flow chromatography test strip view; 1: Trichomonas vaginalis, 2: Trichomonas fetus, 3: Trichomonas murineis, 4: Isospora canis, 5: Giardia lamblia, 6: Cryptosporidium, 7: Toxoplasma gondii, 8: Trichomonas vaginalis, 9: negative control; Figure 8 Sensitivity evaluation results provided in embodiments of the present invention; A is a blue light lamp view, B is a UV lamp view, and C is a side-flow chromatography test strip view; 1: 1.12 × 10 6 copies / μL, 2: 1.12×10 5 copies / μL, 3: 1.12×10 4 copies / μL, 4: 1.12×10 3 copies / μL, 5: 1.12×10 2 copies / μL, 6: 1.12×10 1 copies / μL, 7: 1.12×10 0 copies / μL, 8: 1.12×10 -1 copies / μL, 9: 1.12×10 -2 copies / μL, 10: negative control; Figure 9A view of lateral flow chromatography test strips for 132 canine fecal samples provided in this embodiment of the invention; P: positive control, N: negative control; Figure 10 A view of 71 human fecal samples lateral flow chromatography test strips provided in this embodiment of the invention; P: positive control, N: negative control. Detailed Implementation

[0010] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative and not intended to limit the invention.

[0011] The specific implementation of the present invention will be described in detail below with reference to specific embodiments.

[0012] Example 1: Target Selection and Sequence Validation Choose human 50 cents trichomoniasis ITS1-5.8S-ITS2 The region is a highly conserved target within the species and has a sufficient number of sequence differences with closely related species such as Trichomonas fetus and Trichomonas murineis, making it suitable for species-level identification. The rDNA operon exists in the genome as a multicopy tandem repeat, with high target abundance, which is beneficial for improving detection sensitivity. The target sequence is shown in SEQ ID NO.1 (GenBank accession number: PP297596.1).

[0013] Example 2: RPA primer design and screening: Based on the target sequence, three pairs of candidate primers were designed according to RPA primer design principles. Specific requirements for primer design were: length controlled at 28-35 bp, amplified product length of 150-300 bp, moderate GC content, and avoidance of secondary structures within and between primers. The sequences of the three candidate primer pairs are shown in Table 1. Table 1 RPA primer sequences

[0014] RPA amplification reactions were performed using the three primer pairs mentioned above. The RPA reaction system consisted of 25 μL of the following: 14.75 μL of primer-free rehydration buffer, 1.25 μL of magnesium acetate (MgOAc), 1.25 μL each of 10 μM forward and reverse primers, and 2.5 μL of *Trichomonas vaginalis* genomic DNA template. The remaining volume was made up with deionized water. The reaction conditions were incubation at 37 °C for 20 min. After amplification, 5 μL of the amplification product was mixed with 1 μL of 6× loading buffer and electrophoresed on a 2.5% agarose gel at a constant voltage of 120 V for 30 min. The results were observed using a gel imaging system (e.g., ...). Figure 1 As shown in the figure, the results showed that primer pairs F1 / R1 and F2 / R2 showed non-specific amplification bands at positions of approximately 300 bp and 500 bp, in addition to the target band (approximately 182 bp). In contrast, primer pair F3 / R3 showed only a single, bright band at 182 bp, with no non-specific amplification observed. The negative control (no template) showed no bands. Therefore, F3 / R3 was determined to be the optimal RPA primer pair. The experiments in the subsequent examples used primer pair F3 / R3, whose amplification product length was 182 bp.

[0015] Example 3: Design, in vitro transcription, and screening of crRNA: In the target sequence, a proximal motif (PAM) was sought, and 18-23 nucleotides downstream of the PAM sequence were selected as the target recognition region for crRNA. Simultaneously, sufficient sequence differences in the target region among closely related species were required to ensure specificity. Based on these principles, two candidate crRNAs, crRNA1 and crRNA2, were designed. To obtain these crRNAs via in vitro transcription, two primer pairs, crRNA1-F / R and crRNA2-F / R, were designed and synthesized based on the target sequences of crRNA1 and crRNA2, respectively, for annealing to form a double-stranded DNA transcription template, as shown in Table 2. Table 2. crRNA sequences and corresponding primer sequences for crRNA

[0016] After mixing the primers, an annealing reaction was performed to form a double-stranded DNA template. Transcription was then performed using a high-yield T7 RNA in vitro transcription kit. The transcription reaction system was 20 μL, containing: 4 μL of 5× Transcription Buffer, 1.5 μL of each nucleoside triphosphate solution (NTP Solution), 1.5 μL of Enzyme Mix, 0.5 μL of enzyme-free water, and 0.1–1 μg of the aforementioned double-stranded DNA template. Enzyme-free water was added to a final volume of 20 μL. The mixture was incubated at 37°C for 4 h. After transcription, the DNA was purified using the miRNeasy Mini Kit according to the instructions. The concentration and purity were determined using a NanoDrop Lite spectrophotometer. Degradation was confirmed by electrophoresis at 120 V for 30 min on a 2.5% agarose gel. Figure 2 (As shown), then diluted to 8000 nM and aliquoted for storage; The amplification product from the RPA amplification reaction using primer pair F3 / R3 in Example 2 was mixed with the CRISPR / Cas12a reaction system. The CRISPR / Cas12a reaction system consisted of 40 μL and contained: 200 nM Cas12a protein, 200 nM crRNA (with either crRNA1 or crRNA2 added), 4 μL NEBuffer r3.1, 400 nM FQ-ssDNA reporter molecule (5′-FAM-TTATT-BHQ1-3′), and enzyme-free water to make up the difference. The reaction was carried out at 37°C for 40 min, and the fluorescence signal was collected every 30 s using a real-time PCR instrument. The real-time fluorescence curves of the two crRNAs were compared, and the results are as follows: Figure 3 As shown, the fluorescence value of crRNA2 is higher than that of crRNA1, and no significant fluorescence signal accumulation was observed in the negative control group. Therefore, crRNA2 was selected as the optimal crRNA, and crRNA2 was used in the experiments in the subsequent examples.

[0017] Example 4: Optimization of RPA-CRISPR / Cas12a detection method conditions: To determine the optimal reaction conditions, the RPA reaction time, CRISPR / Cas12a cleavage time, and reaction temperature were optimized. Six RPA reaction gradients were set for 5, 10, 15, 20, 25, and 30 min. The results showed that the amplification product reached a plateau at 20 min (e.g., ...). Figure 4 As shown); the CRISPR / Cas12a cleavage reaction was set with seven gradients at 5, 10, 20, 30, 40, 50, and 60 min. The fluorescence intensity did not significantly increase after 40 min (as shown). Figure 5 (As shown); the reaction temperature was set at five gradients: 33, 35, 37, 39, and 41 ℃. The fluorescence signal was strongest at 37 ℃ (as shown). Figure 6 (as shown in the figure). Therefore, the optimal reaction conditions were determined to be: 37 °C for 20 min for RPA amplification reaction and 37 °C for 40 min for CRISPR / Cas12a cleavage reaction. These reaction conditions were used in the experiments in the subsequent examples.

[0018] Example 5: A method for detecting Trichomonas vaginalis in humans using RPA-CRISPR / Cas12a, comprising the following steps: S1. Extract DNA from the sample to be tested; S2. Referring to Example 2, the DNA of the sample to be tested was subjected to RPA amplification using primer pair F3 / R3 to obtain the amplification product; S3. Referring to Example 3, the amplification product is mixed with the CRISPR / Cas12a reaction system to carry out the CRISPR / Cas12a cleavage reaction. S4. Determine whether the sample to be tested is infected with Trichomonas vaginalis by using fluorescence signals or lateral flow chromatography test strips. The specific interpretation method is as follows: (1) Interpretation of fluorescence signal: FQ-ssDNA reporter molecule (FAM fluorescent group labeled at 5′ end and BHQ1 quencher group labeled at 3′ end) was used during the reaction. After the reaction, the reaction tube was placed under a 365 nm ultraviolet lamp or a 470 nm blue light lamp for observation. If the system emits green fluorescence, it is judged as positive for Trichomonas vaginalis infection; if there is no fluorescence signal, it is judged as negative. (2) Interpretation of lateral flow chromatography test strips: FB-ssDNA reporter molecules (5′ labeled with FAM, 3′ labeled with Biotin) are used during the reaction. The reaction solution is added to the sample pad of the lateral flow chromatography test strip and left to stand for 3-5 minutes before observing the results. If both the test line (T line) and the control line (C line) of the test strip show red bands or only the T line shows a red band, the result is considered positive. If only the C line shows a red band and the T line shows no band, the result is considered negative. (The test strips were purchased from TOLOBIO, product number: 31203.)

[0019] Example 6, Specificity Verification: Trichomonas vaginalis (human hairy trichomoniasis) Pentatrichomonas hominis ), fetal trichomonas ( Tritrichomonas foetus Trichomonas vaginalis ( ) Tritrichomonas muris ), canine coccidia ( Cystoisospora canis Giardia ( Giardia lamblia Cryptosporidium ( Cryptosporidium parvum Toxoplasma gondii ( Toxoplasma gondii ) and Trichomonas vaginalis ( Trichomonas vaginalis Using the genomic DNA of [a specific source] as a template, detection was performed under the optimized conditions described above; such as... Figure 7 As shown, only the Trichomonas vaginalis reaction tube produced a positive fluorescent signal, while the other 7 parasites showed no cross-reaction. The results observed under ultraviolet and blue light were consistent. The test strip detection showed a band only at the detection line position for the Trichomonas vaginalis tube, indicating that the detection composition and method provided in this embodiment of the invention have high specificity.

[0020] Example 7, Sensitivity Evaluation: Constructing the recombinant plasmid pBluescript II KS(-)- containing the target fragment ITS (The plasmid was purchased from Miaoling Biotechnology, product code: P48023). The plasmid was extracted, its concentration was determined, and the copy number was calculated. A qPCR standard curve was established (Ct = -3.3967×log). 10 (copies) + 44.45, R 2=0.9914) Convert the concentration of human Trichomonas vaginalis genomic DNA to copy number; perform 10-fold serial dilutions of the DNA before detection, such as Figure 9 As shown, the detection limit for the fluorescence method is 1.12 copies / μL, and for the test strip method it is 11.2 copies / μL.

[0021] Example 8: Clinical Sample Validation: Validation was performed using 132 canine fecal samples and 71 human fecal samples. Canine fecal samples were collected from the outpatient clinic of the Animal Hospital of Jilin University, and human fecal DNA samples were obtained from previously collected and frozen samples. Genomic DNA was extracted from all samples according to the TIANamp fecal DNA kit instructions before testing. The results showed a positive rate of 12.12% (16 / 132) in dogs. Figure 9 As shown), the positive rate was 8.45% (6 / 71) (as shown). Figure 10 As shown in Table 3, the concordance rate with nested PCR was 100%. Table 3 Comparison of the present invention with nested PCR detection methods

[0022] The above description is merely a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, and improvements made within the spirit and principles of the present invention should be included within the protection scope of the present invention.

Claims

1. A composition for detecting Trichomonas vaginalis in humans, characterized in that, The composition includes crRNA and forward and reverse primers for RPA amplification; The sequence of the forward primer used for RPA amplification is shown in SEQ ID NO.6, and the sequence of the reverse primer used for RPA amplification is shown in SEQ ID NO.

7. The sequence of crRNA is shown in SEQ ID NO.

9.

2. A kit for detecting Trichomonas vaginalis in humans, characterized in that, The kit includes the composition for detecting Trichomonas vaginalis as described in claim 1.